DrugPatentWatch Database Preview

OPTISON Drug Profile

« Back to Dashboard

Which patents cover Optison, and when can generic versions of Optison launch?

Optison is a drug marketed by Ge Healthcare and is included in one NDA. There is one patent protecting this drug.

This drug has forty patent family members in twenty-seven countries.

The generic ingredient in OPTISON is albumin human. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the albumin human profile page.

Summary for OPTISON

International Patents:	40
US Patents:	1
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	32
Clinical Trials:	16
Patent Applications:	1,497
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for OPTISON
Prior Art and Litigation Support	Order Prior Art and Litigation support for OPTISON
DailyMed Link:	OPTISON at DailyMed

Generic Entry Opportunity Date for OPTISON

NDA:

020899

Dosage:

INJECTABLE;INJECTION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for OPTISON

Drug Class	Contrast Agent for Ultrasound Imaging
Mechanism of Action	Ultrasound Contrast Activity

Synonyms for OPTISON

1,1,1,2,2,3,3,3-Octafluoropropane

1,1,1,2,2,3,3,3-octakis(fluoranyl)propane

218599-63-4

300408-51-9

76-19-7

A838638

AC1L1MIR

AC1Q4IBX

AKOS006228213

AN-23892

AN-37829

C-50894

C3F8

C3F8-gas

CHEBI:31980

CHEMBL1663

CK0N3WH0SR

CTK5E2580

D01738

DB-056033

DB00556

Definity

Definity (TN)

DMP 115

DMP-115

DTXSID9052503

EC 200-941-9

EINECS 200-941-9

FC 218

FC 218 (refrigerant)

FCH918400

Flutec PP30

Freon 218

FS-069

FS069

FT-0621948

FT-0631321

Genetron 218

HFC 218

HSDB 8074

I14-14876

KB-59511

liposome-encapsulated perfluoropane microsphere

LS-120891

MRX 115

MRX-115

OCTAFLUOROPROPANE

octafluoropropane-lipid microsphere

Octafluoropropaneor Refrigerant gas R 218

Octafluoropropaneor Refrigerant gas R 218 [UN2424] [Nonflammable gas]

Octafluoropropaneor Refrigerant gas R 218 [UN2424] [Nonflammable gas]

Octafluorpropan

Oktafluorpropan

Optison (Salt/Mix)

Perfluoropropane

Perfluoropropane (PFC-218) 99.9%

Perfluoropropane 99+%

Perfluoropropaneminimum

Perflutren

Perflutren (JAN/USAN/INN)

Perflutren [USAN:INN:BAN]

Perflutren [USAN]

Perflutren and Human Albumin

Perflutren Lipid Microsphere

Perflutren lipid microspheres

Perflutren Protein-Type A Microspheres injection

Perflutren-lipid microsphere

PFC 218

Propane, 1,1,1,2,2,3,3,3-octafluoro-

Propane, octafluoro-

Propane,1,1,1,2,2,3,3,3-octafluoro-

QYSGYZVSCZSLHT-UHFFFAOYSA-N

R 218

RC 218, PFC 218

SBB090673

UN 2424

UN2424

UNII-CK0N3WH0SR

YM454

ZINC8214651

ZX-AP010865

US Patents and Regulatory Information for OPTISON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ge Healthcare	OPTISON	albumin human	INJECTABLE;INJECTION	020899-001	Dec 31, 1997		RX	Yes	Yes			Y

Expired US Patents for OPTISON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ge Healthcare	OPTISON	albumin human	INJECTABLE;INJECTION	020899-001	Dec 31, 1997
Ge Healthcare	OPTISON	albumin human	INJECTABLE;INJECTION	020899-001	Dec 31, 1997
Ge Healthcare	OPTISON	albumin human	INJECTABLE;INJECTION	020899-001	Dec 31, 1997

International Patents for OPTISON

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	9305819
Portugal	100867
Singapore	54121
China	1054545
Israel	103120
Australia	3995997
Czech Republic	286149

Supplementary Protection Certificates for OPTISON

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0961612	2009C/046	Belgium		PRODUCT NAME: PACLITAXEL ALBUMIN; AUTHORISATION NUMBER AND DATE: EU/1/07/428/001 20080111
0961612	C00961612/01	Switzerland		PRODUCT NAME: PACLITAXELUM-ALBUMINUM; REGISTRATION NO/DATE: SWISSMEDIC 63182 26.08.2014
1853250	37/2014	Austria		PRODUCT NAME: PACLITAXEL, DAS ALS ALBUMIN GEBUNDENE NANOPARTIKEL FORMUIERT IST.; REGISTRATION NO/DATE: EU/1/07/428 (MITTEILUNG) (GEAENDERT DURCH C(2013) 9835) 20131230
0961612	09C0050	France		PRODUCT NAME: PACLITAXEL ALBUMINE; REGISTRATION NO/DATE: EU/1/07/428/001 20080111
1853250	238 50005-2014	Slovakia		PRODUCT NAME: PAKLITAXEL VO FORME NANOCASTIC VIAZANYCH NA ALBUMIN; REGISTRATION NO/DATE: EU/1/07/428/001 - EU/1/07/428/002 20131230
1853250	C300673	Netherlands		PRODUCT NAME: PACLITAXEL, GEFORMULEERD ALS ALBUMINE-GEBONDEN NANODEELTJES; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220
0961612	CA 2009 00036	Denmark		PRODUCT NAME: PACLITAXELALBUMIN